BCL2 and lymphoma: In support of this concept, the BCL2 inhibitor venetoclax potentiated the cytotoxic activity of IACS‐010759 in MYC/BCL2 DHL cells, while the Mcl‐1 inhibitor S63845 did so in MYC‐translocated, BCL2‐negative lymphoma cell lines.